Entrada Therapeutics (NASDAQ:TRDA) Stock Bumped Up to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Entrada Therapeutics (NASDAQ:TRDA) from a sell rating to a hold rating in a research note released on Monday morning,Wall Street Zen reports.

Several other equities analysts also recently weighed in on the company. Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Roth Capital reaffirmed a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Finally, HC Wainwright reissued a “neutral” rating on shares of Entrada Therapeutics in a research report on Monday, October 19th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $4.69 on Monday. Entrada Therapeutics has a twelve month low of $4.11 and a twelve month high of $16.45. The stock’s 50 day moving average is $5.75 and its 200 day moving average is $8.54.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.07. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. The business had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $2.30 million. On average, research analysts anticipate that Entrada Therapeutics will post -4.03 EPS for the current year.

Insider Activity at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the sale, the insider directly owned 3,913,952 shares in the company, valued at approximately $29,002,384.32. This trade represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $7.54, for a total value of $199,975.88. Following the sale, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 495,947 shares of company stock worth $3,600,470 over the last ninety days. 9.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its position in Entrada Therapeutics by 14.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 26,776 shares of the company’s stock worth $170,000 after buying an additional 3,326 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Entrada Therapeutics by 24.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 116,596 shares of the company’s stock valued at $740,000 after acquiring an additional 23,058 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Entrada Therapeutics by 118.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 60,704 shares of the company’s stock worth $380,000 after acquiring an additional 32,926 shares during the period. Odyssean LLC bought a new stake in shares of Entrada Therapeutics in the second quarter worth approximately $230,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the second quarter worth approximately $2,212,232. 86.39% of the stock is owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments.

Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.